An interventional study of 600 IU Vitamin D3 in prenatal vitamin and 2000 IU Vitamin D3 in prenatal vitamin in Pregnancy and Vitamin D Deficiency, sponsored by Brigham and Women's Hospital. Completed at 1 site in Mongolia. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-23.
Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Prevention
A double-blind randomized, placebo-controlled trial comparing the impact of 600 IU, 2000 IU, or 4000 IU of Vitamin D3 on third trimester 25(OH)D levels and change from baseline. The Vitamin D will be integrated in a standard prenatal vitamin, which will be taken from 12-16 weeks' gestation and continue throughout pregnancy. Umbilical cord 25(OH)D levels will also be determined. The investigators will generate preliminary data regarding Vitamin D intake and hypertensive disorders, blood pressure, and arterial function measured by tonography. The investigators will independently test blood pressure and proteinuria to identify preeclampsia cases.
Vitamin D deficiency (serum 25(OH)D levels \<20 ng/ml or 50 nmol/l) is widespread among Mongolians and is nearly universal during the winter months. The investigators have conducted a series of studies which have shown nearly universal Vitamin D deficiency in the winter months.
Observational studies in the U.S. have linked low 25(OH)D levels in women to a higher risk of preeclampsia. Mongolians also report levels of preeclampsia that are 3 times higher than those in the U.S (official reports cite 15%, though this may include gestational hypertension).
Given the widespread Vitamin D deficiency in Mongolian women, the high prevalence of hypertensive pregnancy in Mongolia, and the observational studies linking low 25(OH)D levels with preeclampsia risk, the investigators are conducting a pilot Vitamin D dosing trial to:
A double-blind randomized, placebo-controlled trial comparing the impact of 600 IU, 2000 IU, or 4000 IU of Vitamin D3 on third trimester 25(OH)D levels and change from baseline. The Vitamin D will be integrated in a standard prenatal vitamin, which will be taken from 12-16 weeks' gestation and continue throughout pregnancy. Umbilical cord 25(OH)D levels will also be determined. The investigators will generate preliminary data regarding Vitamin D intake and hypertensive disorders, blood pressure, and arterial function measured by tonography. The investigators will independently test blood pressure and proteinuria to identify preeclampsia cases.
The investigators will enroll 360 women who plan to receive their prenatal care and deliver at Zuun Kharaa Hospital in the Selenge province in northern Mongolia. Enrollment will be stratified by season. 120 women will be randomized to each of the three doses of vitamin D (600, 2000, 4000 IU) included in a standard prenatal vitamin.
Calcemia will be monitored two months after randomization and weeks 36-40 of pregnancy. Adverse events of pregnancy will be reported to the Data Safety and Monitoring Board (DSMB) and Institutional Review Board (IRB) per protocol.
Data will be gathered by a Mongolian study coordinator and local clinicians. A DSMB comprised of a U.S. and Mongolian clinicians and statisticians will monitor study data for safety.
801 studies on the registry are indexed under Vitamin D Deficiency; 60 are open to participants now.
This study's enrollment of 360 is above the median of 78 across 590 interventional studies indexed under Vitamin D Deficiency.
Browse Vitamin D Deficiency studies →Brigham and Women's Hospital is the lead sponsor of 1,267 studies on the registry; 228 are open to participants now.
Of its 116 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Women will receive prenatal vitamins containing 600 IU of Vitamin D.
Dietary Supplement: 600 IU Vitamin D3 in prenatal vitamin
Women will receive prenatal vitamins containing 2000 IU of Vitamin D.
Dietary Supplement: 2000 IU Vitamin D3 in prenatal vitamin
Women will receive prenatal vitamins containing 4000 IU of Vitamin D.
Dietary Supplement: 4000 IU Vitamin D3 in prenatal vitamin
Women will receive 600 IU 25(OH)D in prenatal vitamin.
Women will receive 2000 IU 25(OH)D in prenatal vitamin.
Women will receive 4000 IU 25(OH)D in prenatal vitamin.
Total Serum 25(OH)D Concentration
Circulating vitamin D at the end of the study as measured by VIDAS® enzyme linked fluorescent assay (ELFA)
Time frame: 36 weeks gestation or delivery, if delivery occurred before 36 weeks
The Number of Participants With Preeclampsia
Preeclampsia as measured by new onset hypertension after 20 weeks gestation and proteinuria.
Time frame: After 20 weeks gestation
Average Monthly Blood Pressure
Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) were measured in mm Hg at each antenatal care visit by the Study Coordinator, using the Omron- Elite 7300 (Omron Healthcare, Bannockburn, Illinois, USA) automated blood pressure monitor. Three blood pressure readings were taken after at least five minutes seated rest. For the analysis of mean blood pressures at each antenatal visit, the three readings were averaged for each participant.
Time frame: During pregnancy
Arterial Tonometry
Investigators will assess Augmentation Index (AIx) and Pulse Wave Velocity (PWV) by study arm, as measured by AtCor Medical SphygmoCor device. THIS TONOMETER FAILED AND COULD NOT BE REPAIRED, SO WE ARE NOT PRESENTING THESE DATA AS OUTCOMES.
Time frame: 36 weeks gestation
Number of Patients With Preterm Delivery as Measured by Clinical Diagnosis
Gestational age was determined clinically by last menstrual period and by routine first trimester ultrasound which was universal; where these differed by more than 10 days, the ultrasound date was used. Gestational age at delivery was recorded by clinicians and rounded to the nearest week. Preterm delivery was defined as delivery before the 37th week of gestation.
Time frame: During pregnancy
Casarean Section as Measured by Medical Record Abstraction
Cesarean section was abstracted from the labor and delivery chart.
Time frame: Delivery
Assisted Vaginal Delivery as Measured by Medical Record Abstraction
Assisted vaginal delivery with forceps delivery was abstracted from the labor and delivery chart.
Time frame: Delivery
Number of Small for Gestational Age (SGA) Neonates as Measured by Medical Record Abstraction
SGA defined by the lowest 10th percentiles of sex-specific birthweight for gestational age charts of the INTERGROWTH-21st study
Time frame: Delivery
Number of Large for Gestational Age (LGA) Neonates as Measured by Medical Record Abstraction
LGA defined by the highest 10th percentiles of sex-specific birthweight for gestational age charts of the INTERGROWTH-21st study
Time frame: Delivery
Mean Calcemia as Measured by Serum Calcium Test (2mo)
Measured on a semi-automated photometer (Humalyzer 3500, Human Diagnostics, Magdeburg, Germany)
Time frame: 2 months after randomization
Number of Patients With Proteinuria as Measured by Urine Dipstick
Proteinuria at last antenatal visit (usually 36-40 weeks' gestation), measured by 1+ Standard Diagnostics UroColor 10 10 (Kyonggi-do, South Korea) reagent strips
Time frame: 36-40 weeks gestation/delivery
Number of Patients With Hypertensive Disorders of Pregnancy as Measured by Clinical Diagnosis
In Mongolia, clinician-diagnosed preeclampsia may include a blood pressure increases \>30 mm Hg above early pregnancy, with or without documented hypertension, proteinuria, or symptoms such as headache and edema
Time frame: During pregnancy
Number of Patients With Bacterial Vaginosis as Measured by Potassium Hydroxide (KOH) Wet Mount
Bacterial vaginosis was routinely screened by potassium hydroxide wet mount at the first antenatal visit, at 28 weeks' and 32 weeks' gestation. It was also diagnosed by whiff test. We included both wet mount and whiff test positive in the bacterial vaginosis endpoint
Time frame: During pregnancy
Mean Calcemia as Measured by Serum Calcium Test (36-40 Weeks)
Measured on a semi-automated photometer (Humalyzer 3500, Human Diagnostics, Magdeburg, Germany)
Time frame: 36-40 weeks of pregnancy/delivery
| Milestone | 600 IU | 2000 IU | 4000 IU |
|---|---|---|---|
| Started | 119 | 121 | 120 |
| Completed | 112 | 116 | 116 |
| Not completed | 7 | 5 | 4 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 |
| Withdrew: Moved where blood couldn't be collected | 4 | 1 | 3 |
| Withdrew: Fetal loss | 2 | 3 | 1 |
Circulating vitamin D at the end of the study as measured by VIDAS® enzyme linked fluorescent assay (ELFA)
| nmol/l | 600 IU | 2000 IU | 4000 IU |
|---|---|---|---|
| Total Serum 25(OH)D Concentration | 46 ± 21 | 70 ± 23 | 81 ± 29 |
Preeclampsia as measured by new onset hypertension after 20 weeks gestation and proteinuria.
| Participants | 600 IU | 2000 IU | 4000 IU |
|---|---|---|---|
| The Number of Participants With Preeclampsia | 1 | 0 | 0 |
Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) were measured in mm Hg at each antenatal care visit by the Study Coordinator, using the Omron- Elite 7300 (Omron Healthcare, Bannockburn, Illinois, USA) automated blood pressure monitor. Three blood pressure readings were taken after at least five minutes seated rest. For the analysis of mean blood pressures at each antenatal visit, the three readings were averaged for each participant.
| mmHg | 600 IU | 2000 IU | 4000 IU |
|---|---|---|---|
| SBP wk 16-20 | 104.5 ± 9.2 | 104.5 ± 8.7 | 105.5 ± 9.7 |
| SBP wk 20-24 | 105.1 ± 9.0 | 103.6 ± 8.2 | 105.4 ± 8.9 |
| SBP wk 24-28 | 104.9 ± 9.1 | 103.3 ± 8.1 | 104.0 ± 9.3 |
| SBP wk 28-32 | 104.5 ± 8.7 | 103.9 ± 9.7 | 105.4 ± 9.3 |
| SBP wk 36-40 | 110.8 ± 10.1 | 110.6 ± 9.5 | 111.1 ± 11.0 |
| DBP wk 16-20 | 63.8 ± 8.7 | 63.7 ± 8.7 | 65.2 ± 9.0 |
| DBP wk 20-24 | 63.2 ± 9.0 | 63.1 ± 8.6 | 63.8 ± 9.6 |
| DBP wk 24-28 | 64.2 ± 9.8 | 62.6 ± 9.4 | 63.5 ± 9.6 |
| DBP wk 28-32 | 64.4 ± 8.7 | 63.6 ± 9.2 | 65.1 ± 9.2 |
| DBP wk 32-36 | 67.2 ± 8.8 | 66.5 ± 9.4 | 67.1 ± 9.5 |
| DBP wk 36-40 | 70.4 ± 9.7 | 71.0 ± 10.2 | 71.7 ± 10.6 |
Investigators will assess Augmentation Index (AIx) and Pulse Wave Velocity (PWV) by study arm, as measured by AtCor Medical SphygmoCor device. THIS TONOMETER FAILED AND COULD NOT BE REPAIRED, SO WE ARE NOT PRESENTING THESE DATA AS OUTCOMES.
Results for this outcome have not been posted.
Gestational age was determined clinically by last menstrual period and by routine first trimester ultrasound which was universal; where these differed by more than 10 days, the ultrasound date was used. Gestational age at delivery was recorded by clinicians and rounded to the nearest week. Preterm delivery was defined as delivery before the 37th week of gestation.
| Participants | 600 IU | 2000 IU | 4000 IU |
|---|---|---|---|
| Number of Patients With Preterm Delivery as Measured by Clinical Diagnosis | 9 | 8 | 5 |
Cesarean section was abstracted from the labor and delivery chart.
| Participants | 600 IU | 2000 IU | 4000 IU |
|---|---|---|---|
| Casarean Section as Measured by Medical Record Abstraction | 22 | 27 | 26 |
Assisted vaginal delivery with forceps delivery was abstracted from the labor and delivery chart.
| Participants | 600 IU | 2000 IU | 4000 IU |
|---|---|---|---|
| Assisted Vaginal Delivery as Measured by Medical Record Abstraction | 0 | 0 | 0 |
SGA defined by the lowest 10th percentiles of sex-specific birthweight for gestational age charts of the INTERGROWTH-21st study
| Participants | 600 IU | 2000 IU | 4000 IU |
|---|---|---|---|
| Number of Small for Gestational Age (SGA) Neonates as Measured by Medical Record Abstraction | 1 | 2 | 2 |
LGA defined by the highest 10th percentiles of sex-specific birthweight for gestational age charts of the INTERGROWTH-21st study
| Participants | 600 IU | 2000 IU | 4000 IU |
|---|---|---|---|
| Number of Large for Gestational Age (LGA) Neonates as Measured by Medical Record Abstraction | 25 | 26 | 33 |
Measured on a semi-automated photometer (Humalyzer 3500, Human Diagnostics, Magdeburg, Germany)
| mmol/L | 600 IU | 2000 IU | 4000 IU |
|---|---|---|---|
| Mean Calcemia as Measured by Serum Calcium Test (2mo) | 2.2 ± 0.2 | 2.2 ± 0.2 | 2.2 ± 0.2 |
Proteinuria at last antenatal visit (usually 36-40 weeks' gestation), measured by 1+ Standard Diagnostics UroColor 10 10 (Kyonggi-do, South Korea) reagent strips
| Participants | 600 IU | 2000 IU | 4000 IU |
|---|---|---|---|
| Number of Patients With Proteinuria as Measured by Urine Dipstick | 2 | 2 | 0 |
In Mongolia, clinician-diagnosed preeclampsia may include a blood pressure increases \>30 mm Hg above early pregnancy, with or without documented hypertension, proteinuria, or symptoms such as headache and edema
| Participants | 600 IU | 2000 IU | 4000 IU |
|---|---|---|---|
| Number of Patients With Hypertensive Disorders of Pregnancy as Measured by Clinical Diagnosis | 4 | 3 | 3 |
Bacterial vaginosis was routinely screened by potassium hydroxide wet mount at the first antenatal visit, at 28 weeks' and 32 weeks' gestation. It was also diagnosed by whiff test. We included both wet mount and whiff test positive in the bacterial vaginosis endpoint
| Participants | 600 IU | 2000 IU | 4000 IU |
|---|---|---|---|
| Number of Patients With Bacterial Vaginosis as Measured by Potassium Hydroxide (KOH) Wet Mount | 17 | 19 | 18 |
Measured on a semi-automated photometer (Humalyzer 3500, Human Diagnostics, Magdeburg, Germany)
| mmol/L | 600 IU | 2000 IU | 4000 IU |
|---|---|---|---|
| Mean Calcemia as Measured by Serum Calcium Test (36-40 Weeks) | 2.3 ± 0.2 | 2.3 ± 0.2 | 2.3 ± 0.2 |
Collected over From study enrollment (12-16 weeks gestation) to delivery. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 600 IU | 0/119 (0%) | 0/119 (0%) | 0/119 (0%) |
| 2000 IU | 0/121 (0%) | 0/121 (0%) | 0/121 (0%) |
| 4000 IU | 0/120 (0%) | 0/120 (0%) | 0/120 (0%) |
| Age, Categorical(Participants) | 600 IU | 2000 IU | 4000 IU | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 119 | 121 | 120 | 360 |
| >=65 years | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | 600 IU | 2000 IU | 4000 IU | Total |
|---|---|---|---|---|
| Female | 119 | 121 | 120 | 360 |
| Male | 0 | 0 | 0 | 0 |
The record gives a start of Feb 2015, a primary completion of Dec 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2021, 4 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Brigham and Women's Hospital →